Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
April 2, 2026 Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “Company”), a clinical stage...
-
REDWOOD CITY, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today...
-
SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic...
-
Alberta's dentists are encouraging Albertans to get back to the basics of oral health — and to have a conversation their dental team about oral cancer.
-
BALTIMORE, April 01, 2026 (GLOBE NEWSWIRE) -- It only takes one check to make a real impact! This April, during Testicular Cancer Awareness Month, the Urology Care Foundation (UCF)—the official...
-
SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic...
-
EDMONTON, Alberta, March 31, 2026 (GLOBE NEWSWIRE) -- When you sit down for a routine dental visit, your oral health professional is doing more than checking your teeth. They are also examining the...
-
Announced partnership with Australian CRO to accelerate initiation of CLD-401 clinical trialThe Company has received feedback from the FDA through Type D interactions, and the Company believes its...
-
Presentation of the molecular structure, discovery, and preclinical data supporting the potential best-in-class profile of PARG inhibitor FORX-428.
-
The Io Therapeutics, Inc. clinical stage anti-cancer RXR agonist compound demonstrated efficacy in models of human multiple myeloma.